Immuneering Corporation Class A Common Stock (IMRX)

About IMRX

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical tri…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

57

Website

immuneering.com/

Fundamentals

1-day range

$4.94$5.21

Market cap

$269.79M

P/E (trailing)

—

P/E (forward)

-3.87

EPS (trailing)

$-1.03

Dividend yield

—

Beta

0.33

Avg. volume

1.22M

Forecasts

7 analyst ratings

Immuneering Corporation Class A Common Stock Competitors

Chosen by industry and closest market cap.

• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $269.79MP/E —
  $3.86$10.08
• BCYC

  Bicycle Therapeutics plc American Depositary Shares

  $4.21

  ▼ 2.77%
  Market cap $270.87MP/E —
  $3.75$9.16
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $264.75MP/E —
  $1.35$4.6
• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $259.71MP/E —
  $0.96$2.66
• VRXA

  Veraxa Biotech AG Ordinary Shares

  $1.36

  ▼ 5.56%
  Market cap $258.78MP/E —
  $1.32$27.36
• FULC

  Fulcrum Therapeutics Inc. Common Stock

  $3.85

  ▲ 0.00%
  Market cap $283.06MP/E —
  $2.83$15.74
• MGNX

  MacroGenics Inc. Common Stock

  $4.13

  ▲ 1.23%
  Market cap $242.81MP/E —
  $1.29$5.08

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment
  benzinga · 8/26/2026
• This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
  Benzinga · 8/6/2026
• HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14
  Benzinga · 8/6/2026
• Immuneering Q2 EPS $(0.27), Inline
  Benzinga · 8/5/2026

• Andrew Gengos · July 16, 2026 · Grant

  650.0K
• Benjamin J. Zeskind · June 23, 2026 · Buy

  2.4K @ $4.56
• Brett Matthew Hall · June 15, 2026 · Buy

  6.0K @ $4.15
• Peter Feinberg · June 11, 2026 · Grant

  33.4K
• KEATING LAURIE · June 11, 2026 · Grant

  33.4K
• Diana Hausman · June 11, 2026 · Grant

  33.4K
• Thomas J. Schall · June 11, 2026 · Grant

  33.4K
• CARPENTER ROBERT J · June 11, 2026 · Grant

  33.4K
• Leah R. Neufeld · March 13, 2026 · Grant

  3.6K @ $4.29

Institutional Ownership

March 31, 2026

Total shares held

27.22M

Total value held

$133.03M

Institutional holders

92